A bone-seeking clone exhibits different biological properties from the ACHN parental human renal cell carcinoma in vivo and in vitro

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1104-1110

  Wang, Jiang ^a   Chen, Anmin ^a   Yang, Caihong ^a   Zeng, Heng ^a   Qi, Jun ^a   Guo, Feng Jin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Animal model development; Bone metastasis; In vivo selection; Renal cell carcinoma

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CLONE CELLS; CYTOKINES; FEMALE; FEMORAL NEOPLASMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOLYSIS; PHENOTYPE; S PHASE; TIBIA; TIME FACTORS;

EID: 84863050279     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1572     Document Type: Article

References (38)

1. Figlin RA: Renal cell carcinoma: management of advanced disease. J Urol 161: 381-387, 1999.
2. Zekri J, Ahmed N, Coleman RE and Hancock BW: The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19: 379-382, 2001.
3. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004. (Pubitemid 38443417)
4. Galasko CS: Bone metastases studied in experimental animals. Clin Orthop Relat Res 1981: 269-285, 1981.
5. Durr HR, Maier M, Pfahler M, Baur A and Refior HJ: Surgical treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 283-290, 1999. (Pubitemid 29503706)
6. Iwai A, Fujii Y, Kawakami S, et al: Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids. Mol Cell Endocrinol 226: 11-17, 2004. (Pubitemid 39369818)
7. Takahashi A, Sasaki H, Kim SJ, et al: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4233-4237, 1994. (Pubitemid 24258135)
8. Motzer RJ and Russo P: Systemic therapy for renal cell carcinoma. J Urol 163: 408-417, 2000. (Pubitemid 30060482)
9. Weber K, Doucet M and Kominsky S: Renal cell carcinoma bone metastasis - elucidating the molecular targets. Cancer Metastasis Rev 26: 691-704, 2007. (Pubitemid 350115120)
10. Takahashi N, MacDonald BR, Hon J, et al: Recombinant human transforming growth factor-alpha stimulates the formation of osteoclast-like cells in long-term human marrow cultures. J Clin Invest 78: 894-898, 1986. (Pubitemid 17177067)
11. Kominsky SL, Doucet M, Brady K and Weber KL: TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. J Bone Miner Res 22: 37-44, 2007. (Pubitemid 46032595)
12. Mydlo JH, Michaeli J, Cordon-Cardo C, Goldenberg AS, Heston WD and Fair WR: Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 49: 3407-3411, 1989. (Pubitemid 19162159)
13. Aebersold DM, Froehlich SC, Jonczy M, et al: Expression of transforming growth factor-alpha, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiother Oncol 63: 275-283, 2002. (Pubitemid 34874555)
14. Pan J, Mestas J, Burdick MD, et al: Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 5: 56, 2006.
15. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S and Contag CH: Animal models of bone metastasis. Cancer 97: 748-757, 2003. (Pubitemid 36125810)
16. Arguello F, Baggs RB and Frantz CN: A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48: 6876-6881, 1988. (Pubitemid 19012221)
17. Yoneda T, Sasaki A, Dunstan C, et al: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99: 2509-2517, 1997. (Pubitemid 27227730)
18. Otsuka S, Hanibuchi M, Ikuta K, et al: A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. Oncol Res 17: 581-591, 2009.
19. Liu H, Chen A, Guo F and Yuan L: A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 295: 27-37, 2010.
20. Kelland LR: Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40: 827-836, 2004.
21. Bibby MC: Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40: 852-857, 2004.
22. Hawk ET, Umar A, Lubet RA, Kopelovich L and Viner JL: Can animal models help us select specific compounds for cancer prevention trials? Recent Results Cancer Res 166: 71-87, 2005.
23. Shaw TJ, Senterman MK, Dawson K, Crane CA and Vanderhyden BC: Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10: 1032-1042, 2004. (Pubitemid 39625247)
24. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE and Klagsbrun M: Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261: 12665-12674, 1986. (Pubitemid 17204223)
25. Pfeilschifter J and Mundy GR: Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 84: 2024-2028, 1987. (Pubitemid 17054142)
26. Kretzschmar M, Doody J, Timokhina I and Massague J: A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 13: 804-816, 1999. (Pubitemid 29169840)
27. Luo K, Stroschein SL, Wang W, et al: The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev 13: 2196-2206, 1999. (Pubitemid 29426725)
28. Onichtchouk D, Chen YG, Dosch R, et al: Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401: 480-485, 1999. (Pubitemid 29470206)
29. Stroschein SL, Wang W, Zhou S, Zhou Q and Luo K: Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 286: 771-774, 1999.
30. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380, 2002.
31. Rini BI and Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028-1043, 2005. (Pubitemid 46202321)
32. Gorospe M, Egan JM, Zbar B, et al: Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol Cell Biol 19: 1289-1300, 1999. (Pubitemid 29046871)
33. Semenza G: Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64: 993-998, 2002.
34. Iguchi H, Yokota M, Fukutomi M, et al: A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 21: 309-313, 2002.
35. Yang Q, McHugh KP, Patntirapong S, Gu X, Wunderlich L and Hauschka PV: VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol 27: 589-599, 2008.
36. Hurley MM, Lee SK, Raisz LG, Bernecker P and Lorenzo J: Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. Bone 22: 309-316, 1998. (Pubitemid 28177182)
37. Blay JY, Negrier S, Combaret V, et al: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322, 1992.
38. Negrier S, Perol D, Menetrier-Caux C, et al: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie. J Clin Oncol 22: 2371-2378, 2004. (Pubitemid 41115394)